No effect of anti-TNF-α agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study

BMC Surg. 2018 Nov 3;18(1):91. doi: 10.1186/s12893-018-0425-0.

Abstract

Background: TNF-α plays a role in angiogenesis and collagen synthesis, both essential in the wound healing process. There are concerns that pre-operative anti-TNF-α treatment may influence the surgical stress response and increase the risk of surgical complications. The aim of this study was to describe the surgical stress response in patients with inflammatory bowel disease (IBD) and to investigate whether the pre-operative administration of anti-tumor necrosis factor alpha (anti-TNF-α) agents modify the surgical stress response.

Methods: This was a prospective, multi-center cohort pilot study. The primary outcome was the change in concentration of immunological biomarkers of the surgical stress response (TNF-α, IL-6, and IL-10). Secondary outcome measures were changes in IL-8, IL-17A, C-reactive protein, white blood cells, cortisol, transferrin, ferritin, and D-Dimer in addition to 30 days' post-operative complications and length of post-operative stay in the hospital (LOS).

Results: Forty-six patients with IBD undergoing major abdominal surgery were included, and 18 received anti-TNF- α treatment pre-operatively. Peak increase of most of the immunological biomarkers occurred 6 hours after surgical incision. Then the concentration decreased after 24 h followed by a plateau at 48 h. After adjusting for confounders including detectable blood concentrations, no difference in the concentrations of immunological, endocrinological or haematological biomarkers of stress was found between anti-TNF-α treated and anti-TNF-α naïve patients. No increase in post-operative complications or LOS was noticed in patients who received anti-TNF-α treatment.

Conclusions: Anti-TNF-α did not affect surgical stress response in this pilot study. Withdrawal of anti-TNF-α drugs prior to surgical intervention in IBD patients might not be justified without measurement of drug concentration and drug antibodies.

Trial registration: Clinicaltrails.gov.: NCT01974869 .

Keywords: Anastomotic leak; Anti-TNF alpha; Crohn’s disease; Inflammatory bowel disease; Interleukins; Surgical stress response; Ulcerative colitis; Wound healing.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Biomarkers / blood
  • Cytokines / blood*
  • Digestive System Surgical Procedures*
  • Female
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Inflammatory Bowel Diseases / blood
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / surgery
  • Infliximab / therapeutic use*
  • Male
  • Pilot Projects
  • Postoperative Complications / blood
  • Postoperative Complications / prevention & control*
  • Preoperative Period
  • Prospective Studies
  • Risk Factors
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Biomarkers
  • Cytokines
  • Gastrointestinal Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab

Associated data

  • ClinicalTrials.gov/NCT01974869